All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Security
Security
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

PEP-EDIT: A Web Server for 3D Generation and Interactive Editing of Complex Peptide Structures

By

Chevrollier, Nicolas, Dougha, Alexis, Ye, Celine, Stratmann, Dirk, Moroy, Gautier, Rey, Julien, Murail, Samuel, Tufféry, Pierre

10d ago· 18 min readenNews

Summary

This article presents PEP-EDIT, a web server tool designed for generating and interactively editing 3D structures of complex peptides. It addresses the growing need in peptide drug development for accessible tools that can handle non-standard amino acids, non-amino components, multicyclic structures, branching, and other complex topologies. The tool enables researchers to generate and modify 1D, 2D, and 3D representations of complex peptides as a starting point for further optimization in drug discovery.

Source

bskyPEP-EDIT: A Web Server for 3D Generation and Interactive Editing of Complex Peptide Structuresdoi.org

Key quotes

· 4 pulled
In recent years, the development of peptide drugs has seen significant growth.
These molecules often go beyond simple linear chains composed of the standard 20 amino acids.
Peptide drugs frequently incorporate non-standard amino acids, non-amino components, and can exhibit mono- or multicyclic structures, branching, and other complex topologies.
Consequently, there is a growing need for accessible tools that allow researchers to easily generate and modify 1D, 2D, and 3D representations of these complex peptides.
Snippet from the RSS feed
Abstract. In recent years, the development of peptide drugs has seen significant growth. These molecules often go beyond simple linear chains composed of t

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.